Management of Pediatric Cellulitis in Patients with Penicillin Allergy

Outpatient Treatment – Non‑purulent Cellulitis

Clindamycin is the preferred first‑line oral agent (10–13 mg/kg dose every 6–8 h, max 40 mg/kg/day) because it covers both β‑hemolytic streptococci and community‑associated MRSA. 1
A 5–10‑day course is recommended, adjusted according to clinical response. 4
If clindamycin cannot be used, linezolid (10 mg/kg dose every 8 h, not exceeding 600 mg per dose in children < 12 y; 600 mg PO twice daily in children ≥ 12 y) provides comparable dual coverage. 2
For children ≥ 8 years, doxycycline (2 mg/kg dose every 12 h, or 100 mg PO twice daily if ≥ 45 kg) may be used only in combination with a non‑penicillin β‑lactam because its activity against β‑hemolytic streptococci is uncertain; doxycycline is contraindicated in children < 8 years. 3

Clindamycin remains the first‑line oral therapy (same dosing as for non‑purulent disease). 2
Trimethoprim‑sulfamethoxazole (trimethoprim 4–6 mg/kg dose every 12 h) can be added for MRSA coverage but should not be used alone because it does not reliably cover β‑hemolytic streptococci; it is contraindicated in infants < 2 months. 3

Vancomycin 15 mg/kg IV every 6 h is the gold‑standard first‑line IV therapy for severe disease. 5
Clindamycin IV (10–13 mg/kg dose every 6–8 h, max 40 mg/kg/day) is an alternative when institutional clindamycin resistance is <10 % and the patient is clinically stable; patients may be switched to oral therapy if the isolate is susceptible. 4
Linezolid (same dosing as outpatient, IV or PO) is a further alternative when vancomycin or clindamycin are unsuitable. 5
The recommended duration for complicated infections is 7–14 days, guided by clinical improvement. 1

Do not use TMP‑SMX or tetracyclines as monotherapy for non‑purulent cellulitis because of inadequate streptococcal activity. 2
Never prescribe tetracyclines to children < 8 years of age. 4
Avoid TMP‑SMX in infants < 2 months. 3
Rifampin should not be used as monotherapy or adjunctive therapy for cellulitis. 1
Inducible clindamycin resistance precludes its use in serious infections. 2
Clindamycin carries a higher risk of Clostridioides difficile infection compared with other oral agents. 2

Admit children with cellulitis who develop any of the following: systemic inflammatory response syndrome, altered mental status, hemodynamic instability, suspicion of deep or necrotizing infection, immunocompromised status, or failure of outpatient therapy. These criteria identify patients who require inpatient care. 6

Although first‑generation cephalosporins have a cross‑reactivity rate of <2 % in patients reporting penicillin allergy, the safest approach for pediatric patients with a confirmed penicillin allergy is to use clindamycin or other non‑β‑lactam agents as outlined above. This avoids potential severe allergic reactions while ensuring adequate antimicrobial coverage. 1